# Only 1 in 5 Older Cannabis Users Tell Doctors | Trending – Labroots > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/only-1-in-5-older-cannabis-users-tell-doctors-trending-labroots/ > **Published:** 2026-06-14T00:06:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:46-04:00 > **Clinical Summary:** Study reveals why older adults cannabis disclosure to clinicians remains low. Clinical gaps in geriatric cannabis screening and safety. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AgingResearchSafetyMental HealthPolicyPainAnxiety Why This Matters Clinicians may be unaware of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in 80% of older patients who use it, creating a critical gap in medication interaction screening and adverse event identification since cannabis can potentiate sedatives, anticoagulants, and other commonly prescribed geriatric medications. This disclosure gap prevents clinicians from providing evidence-based counseling on [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/), dosing, and alternatives for conditions like [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) and insomnia that older adults frequently self-treat with cannabis. Establishing trust-based communication about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and developing standardized screening protocols is essential for delivering comprehensive geriatric care and reducing preventable drug interactions and falls. Clinical Summary A recent study demonstrates that fewer than 20% of older adults who use cannabis disclose this use to their physicians, representing a significant gap in clinical communication that may compromise [patient safety](https://cedclinic.com/indiana-marijuana-legalization-policy-addressing-lagging-reform/) and care quality. This disclosure failure occurs despite the lack of established clinical guidance on [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in older populations, leaving physicians unable to assess potential drug interactions, contraindications, or age-related risks associated with cannabis products. The study underscores a critical challenge in geriatric medicine, as older adults may be using [cannabis for pain](https://cedclinic.com/cannabis-veterans-substance-use-disorder-study/), anxiety, or sleep without their healthcare providers’ knowledge, potentially compounding risks from polypharmacy or underlying medical conditions common in this age group. The communication barrier may stem from patient concerns about legal consequences, physician judgment, or lack of awareness about the relevance of cannabis to their medical care. Clinicians should proactively establish a non-judgmental clinical environment and specifically ask older patients about cannabis use during medication reviews and comprehensive assessments, as this disclosure is essential for identifying drug interactions and optimizing treatment safety in an aging population increasingly turning to cannabis products. Dr. Caplan’s Take “The fact that 80 percent of older cannabis users aren’t disclosing to their physicians represents a genuine [patient safety](https://cedclinic.com/indiana-marijuana-legalization-policy-addressing-lagging-reform/) gap, because we can’t effectively manage drug interactions, monitor for adverse effects, or adjust other medications intelligently when we don’t have complete information about what patients are actually taking.” Clinical Perspective 💊 The underreporting of cannabis use among older adults represents a significant clinical blind spot that could compromise medication safety and clinical decision-making. This communication gap is particularly concerning given that older patients often take multiple medications with potential cannabinoid interactions, have age-related changes in drug metabolism, and may experience cannabis-related adverse effects (such as falls or cognitive changes) that clinicians might misattribute to other causes. The reasons for non-disclosure are likely multifactorial, including lingering stigma, uncertainty about legal status, assumptions that doctors disapprove, or simply not perceiving cannabis as a “medication” worth reporting. Clinicians should proactively and non-judgmentally ask about cannabis use as part of comprehensive medication reconciliation in older populations, similar to alcohol and supplement screening, while being prepared to discuss potential risks including drug interactions, fall risk, and cardiovascular effects in this vulnerable age group. Creating a normalized, judgment-free environment 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/medical-illness/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Only%201%20in%205%20Older%20Cannabis%20Users%20Tell%20Doctors%20%7C%20Trending%20-%20Labroots%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59002)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59002)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Only%201%20in%205%20Older%20Cannabis%20Users%20Tell%20Doctors%20%7C%20Trending%20-%20Labroots%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59002)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://www.labroots.com/trending/cannabis-sciences/30657/1-5-cannabis-users-tell-doctors/amp](https://www.labroots.com/trending/cannabis-sciences/30657/1-5-cannabis-users-tell-doctors/amp) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).